載入...
Itolizumab in Psoriasis
A number of biologics is being used for the treatment of psoriasis. Itolizumab is one such agent which has been approved in India. It is an anti-CD6 monoclonal antibody that acts by binding to scavenger receptor cysteine-rich (SRCR) distal domain 1 of CD6. Itolizumab has been found to be safe, with...
Na minha lista:
| 發表在: | Indian J Dermatol |
|---|---|
| 主要作者: | |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Medknow Publications & Media Pvt Ltd
2017
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5527725/ https://ncbi.nlm.nih.gov/pubmed/28794555 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4103/ijd.IJD_467_16 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|